Inhibikase Therapeutics
IKT
IKT
47 hedge funds and large institutions have $113M invested in Inhibikase Therapeutics in 2025 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 12 increasing their positions, 3 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
47
Holders Change
+16
Holders Change %
+51.61%
% of All Funds
0.64%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
19
Increased
12
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Millennium Management
New York
|
+$1.69M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.11M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$340K |
| 4 |
Goldman Sachs
New York
|
+$267K |
| 5 |
Jane Street
New York
|
+$255K |
Top Sellers
| 1 |
CC
Commodore Capital
New York
|
-$1.27M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$476K |
| 3 |
Citigroup
New York
|
-$112K |
| 4 |
AGM
Alpine Global Management
New York
|
-$96.5K |
| 5 |
Squarepoint
New York
|
-$92.3K |
